Evidence map›Paper›PMID 29923322›Full record

SynthesisJournal of diabetes investigation2019

Effects of sodium-glucose cotransporter 2 inhibitors in addition to insulin therapy on cardiovascular risk factors in type 2 diabetes patients: A meta-analysis of randomized controlled trials.

Bingshu Wu, Hongzhi Zheng, Jianqiu Gu, Yan Guo, Yixuan Liu, Yingfang Wang, Feng Chen, Aolin Yang, Jiabei Wang, Hailong Wang and 2 more

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of diabetes investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. New perspectives on insulin therapy.Journal of diabetes investigation · 2020
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Bingshu WuDepartment of Geriatric Endocrinology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.ORCID http://orcid.org/0000-0002-7734-304X
Hongzhi ZhengDepartment of Geriatric Endocrinology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Jianqiu GuDepartment of Endocrinology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Yan GuoDepartment of Geriatric Endocrinology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Yixuan LiuDepartment of Geriatric Endocrinology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Yingfang WangDepartment of Geriatric Endocrinology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Feng ChenDepartment of Geriatric Endocrinology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Aolin YangDepartment of Geriatric Endocrinology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Jiabei WangDepartment of Geriatric Endocrinology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Hailong WangDepartment of Epidemiology and Evidence-based Medicine, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Ying LiuDepartment of Biochemistry and Molecular Biology, China Medical University, Shenyang, Liaoning, China.
Difei WangDepartment of Geriatric Endocrinology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.

Funding

Local Development Foundation of Science and Technology guided by the Central Commission 2016007024National Natural Science Foundation of China 31570819Science and Technology Projects of Liaoning Province 2015225024
6 · The paper itself

Abstract

AIMS/

introductionIn the present meta-analysis, we aimed to determine the effects of sodium-glucose cotransporter 2 inhibitor (SGLT-2i) in addition to insulin therapy on cardiovascular risk factors in type 2 diabetes patients. MATERIALS AND

methodsRandomized controlled trials were identified by searching the PubMed, Embase and Cochrane Library databases published before September 2017. The intervention group received SGLT-2i as add-on treatment to insulin therapy, and the control group received placebos in addition to insulin. We assessed pooled data, including weighted mean differences and 95% confidence intervals (CIs) using a random-effects model.

resultsA total of 10 randomized controlled trials (n = 5,159) were eligible. The weighted mean differences for systolic blood pressure and diastolic blood pressure were -3.17 mmHg (95% CI -4.53, -1.80, I

conclusionsThe results showed that in the intervention group, greater reductions were achieved for blood pressure, glucose control, uric acid and bodyweight. This treatment regimen might therefore provide beneficial effects on the occurrence and development of cardiovascular events.

Indexed as

Cardiovascular DiseasesChinaDiabetes Mellitus, Type 2Drug Therapy, CombinationHumansHypoglycemic AgentsIncidencePrognosisRandomized Controlled Trials as TopicRisk FactorsSodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsCardiovascular risk factorsMeta-analysisSodium-glucose cotransporter 2 inhibitor

Identifiers

PMID29923322
PMCPMC6400156

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.